SCHEMBL19997395

SCHEMBL19997395

CSc1nc(N)c2ncc(C3(O)O[C@@H]4C(OCc5ccccc5)[C@]4(OCc4ccccc4)[C@@]3(C)OCc3ccccc3)n2n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19997428 1.00 — —
SCHEMBL19997384 0.91 — —
SCHEMBL24168593 0.90 DCPS (0.31) —
SCHEMBL20380392 0.87 — —
SCHEMBL19997433 0.87 TLR7 (0.31) —
SCHEMBL23278043 0.87 TLR7 (0.31) —
SCHEMBL19997439 0.84 TNK2 (0.36) —
SCHEMBL12243146 0.82 HSPA5 (0.34) —
SCHEMBL12393303 0.78 — —
SCHEMBL20380389 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988498-B2 Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs GILEAD SCIENCES, INC. (US) 2021-04-27 — — US disclosed
US-RE46762-E1 1′-substituted carba-nucleoside analogs for antiviral treatment GILEAD SCIENCES, INC (US) 2018-03-27 — — US disclosed
Send feedback